FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308551039> ?p ?o ?g. }

• W4308551039 endingPage "858" @default.
• W4308551039 startingPage "849" @default.
• W4308551039 abstract "Targeted α-therapy (TAT) for prostate-specific membrane antigen (PSMA) is a promising treatment for metastatic castration-resistant prostate cancer (CRPC). Astatine is an α-emitter (half-life=7.2 h) that can be produced by a 30-MeV cyclotron. This study evaluated the treatment effect of 211At-labeled PSMA compounds in mouse xenograft models.Tumor xenograft models were established by subcutaneous transplantation of human prostate cancer cells (LNCaP) in NOD/SCID mouse. [211At]PSMA1, [211At]PSMA5, or [211At]PSMA6 was administered to LNCaP xenograft mice to evaluate biodistribution at 3 and 24 h. The treatment effect was evaluated by administering [211At]PSMA1 (0.40 ± 0.07 MBq), [211At]PSMA5 (0.39 ± 0.03 MBq), or saline. Histopathological evaluation was performed for the at-risk organs at 3 and 6 weeks after administration.[211At]PSMA5 resulted in higher tumor retention compared to [211At]PSMA1 and [211At]PSMA6 (30.6 ± 17.8, 12.4 ± 4.8, and 19.1 ± 4.5 %ID/g at 3 h versus 40.7 ± 2.6, 8.7 ± 3.5, and 18.1 ± 2.2%ID/g at 24 h, respectively), whereas kidney excretion was superior in [211At]PSMA1 compared to [211At]PSMA5 and [211At]PSMA6. An excellent treatment effect on tumor growth was observed after [211At]PSMA5 administration. [211At]PSMA1 also showed a substantial treatment effect; however, the tumor size was relatively larger compared to that with [211At]PSMA5. In the histopathological evaluation, regenerated tubules were detected in the kidneys at 3 and 6 weeks after the administration of [211At]PSMA5.TAT using [211At]PSMA5 resulted in excellent tumor growth suppression with minimal side effects in the normal organs. [211At]PSMA5 should be considered a new possible TAT for metastatic CRPC, and translational prospective trials are warranted." @default.
• W4308551039 created "2022-11-12" @default.
• W4308551039 creator A5020818857 @default.
• W4308551039 creator A5021151911 @default.
• W4308551039 creator A5030488812 @default.
• W4308551039 creator A5032338769 @default.
• W4308551039 creator A5033771348 @default.
• W4308551039 creator A5034265751 @default.
• W4308551039 creator A5034622699 @default.
• W4308551039 creator A5035678565 @default.
• W4308551039 creator A5035960100 @default.
• W4308551039 creator A5060870414 @default.
• W4308551039 creator A5082210818 @default.
• W4308551039 creator A5082627299 @default.
• W4308551039 date "2022-11-08" @default.
• W4308551039 modified "2023-10-18" @default.
• W4308551039 title "Targeted α-therapy using astatine (211At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound" @default.
• W4308551039 cites W1904433804 @default.
• W4308551039 cites W1964785067 @default.
• W4308551039 cites W1987233672 @default.
• W4308551039 cites W2106506685 @default.
• W4308551039 cites W2179708332 @default.
• W4308551039 cites W2403516958 @default.
• W4308551039 cites W2467018059 @default.
• W4308551039 cites W2541665535 @default.
• W4308551039 cites W2554535346 @default.
• W4308551039 cites W2603592198 @default.
• W4308551039 cites W2792310205 @default.
• W4308551039 cites W2804630210 @default.
• W4308551039 cites W2883030921 @default.
• W4308551039 cites W2915242013 @default.
• W4308551039 cites W2924922394 @default.
• W4308551039 cites W3016674508 @default.
• W4308551039 cites W3068427821 @default.
• W4308551039 cites W3084814365 @default.
• W4308551039 cites W3109853059 @default.
• W4308551039 cites W3112030517 @default.
• W4308551039 cites W3128646645 @default.
• W4308551039 cites W3135424945 @default.
• W4308551039 cites W3135583029 @default.
• W4308551039 cites W3154873246 @default.
• W4308551039 cites W3161342297 @default.
• W4308551039 cites W3175615655 @default.
• W4308551039 cites W3176208875 @default.
• W4308551039 cites W3177740248 @default.
• W4308551039 cites W3194196649 @default.
• W4308551039 cites W4225256013 @default.
• W4308551039 doi "https://doi.org/10.1007/s00259-022-06016-z" @default.
• W4308551039 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36344651" @default.
• W4308551039 hasPublicationYear "2022" @default.
• W4308551039 type Work @default.
• W4308551039 citedByCount "6" @default.
• W4308551039 countsByYear W43085510392023 @default.
• W4308551039 crossrefType "journal-article" @default.
• W4308551039 hasAuthorship W4308551039A5020818857 @default.
• W4308551039 hasAuthorship W4308551039A5021151911 @default.
• W4308551039 hasAuthorship W4308551039A5030488812 @default.
• W4308551039 hasAuthorship W4308551039A5032338769 @default.
• W4308551039 hasAuthorship W4308551039A5033771348 @default.
• W4308551039 hasAuthorship W4308551039A5034265751 @default.
• W4308551039 hasAuthorship W4308551039A5034622699 @default.
• W4308551039 hasAuthorship W4308551039A5035678565 @default.
• W4308551039 hasAuthorship W4308551039A5035960100 @default.
• W4308551039 hasAuthorship W4308551039A5060870414 @default.
• W4308551039 hasAuthorship W4308551039A5082210818 @default.
• W4308551039 hasAuthorship W4308551039A5082627299 @default.
• W4308551039 hasBestOaLocation W43085510391 @default.
• W4308551039 hasConcept C121608353 @default.
• W4308551039 hasConcept C126322002 @default.
• W4308551039 hasConcept C185592680 @default.
• W4308551039 hasConcept C202751555 @default.
• W4308551039 hasConcept C2777807558 @default.
• W4308551039 hasConcept C2779723316 @default.
• W4308551039 hasConcept C2780091579 @default.
• W4308551039 hasConcept C2780192828 @default.
• W4308551039 hasConcept C2911091166 @default.
• W4308551039 hasConcept C2989005 @default.
• W4308551039 hasConcept C2993559085 @default.
• W4308551039 hasConcept C502942594 @default.
• W4308551039 hasConcept C55493867 @default.
• W4308551039 hasConcept C71924100 @default.
• W4308551039 hasConcept C98274493 @default.
• W4308551039 hasConceptScore W4308551039C121608353 @default.
• W4308551039 hasConceptScore W4308551039C126322002 @default.
• W4308551039 hasConceptScore W4308551039C185592680 @default.
• W4308551039 hasConceptScore W4308551039C202751555 @default.
• W4308551039 hasConceptScore W4308551039C2777807558 @default.
• W4308551039 hasConceptScore W4308551039C2779723316 @default.
• W4308551039 hasConceptScore W4308551039C2780091579 @default.
• W4308551039 hasConceptScore W4308551039C2780192828 @default.
• W4308551039 hasConceptScore W4308551039C2911091166 @default.
• W4308551039 hasConceptScore W4308551039C2989005 @default.
• W4308551039 hasConceptScore W4308551039C2993559085 @default.
• W4308551039 hasConceptScore W4308551039C502942594 @default.
• W4308551039 hasConceptScore W4308551039C55493867 @default.
• W4308551039 hasConceptScore W4308551039C71924100 @default.
• W4308551039 hasConceptScore W4308551039C98274493 @default.
• W4308551039 hasFunder F4320311405 @default.

• next